Tuesday, October 31, 2017

Gods cricket chorus

Monday, October 9, 2017

STRENGTH IN NUMBERS


Calling all victims of CDC’s Lyme Cryme! TRUTHCURES recently made contact with members of the U.S. House of Representatives Committee on Oversight and Government Reform. We told them that it’s their job to protect us from the CDC cabal who have not allowed the diagnosis of neurologic Lyme disease since 1994. Want to join us? Go to their Website and blow the whistle. You may copy and paste the text from below directly into the form.
Organization:
CDC officers

Details:
We urge the Committee on Oversight and Government Reform to hold a hearing for the purpose of compelling the U.S. Department of Justice to prosecute the cabal fronted by the American Lyme Disease Foundation (ALDF) that was founded in 1990 by CDC officers and their associates at Yale and New York Medical College. Under the Bayh-Dole Act, they intended to capitalize on emerging vector-borne diseases with intent to deny basic human rights to an entire class of victims of their scientific research and medical fraud and continued abuses under color of law.

The main crime revolves around the falsification of the case definition (diagnostic testing) of Lyme disease at the CDC’s 1994 Second National Conference on Serologic Diagnosis of Lyme Disease (hereafter referred to as “Dearborn”).

At a 2001 FDA meeting, whistleblower testimony proved that Dearborn was not a consensus (average accuracy was 15%, or missed 85% of the cases), that the cabal’s first product to hit the market, LYMErix/OspA, caused immunosuppression, and that it caused a “multi-system” disease that is “indistinguishable” (Persing, Schoen) from the chronic, post sepsis Lyme that was eliminated from the case definition. This falsified, current case definition includes ONLY a short term, self-resolving, temporary “autoimmune,” Lyme arthritis and needs no medical care, as these criminals themselves claim.

These racketeers who own patents for vector-borne disease test kits and vaccines were the same ones who falsified the case definition at Dearborn, and were also the same ones who sat on the FDA committees to approve their own fake OspA (fungal endotoxin) “vaccines” such as LYMErix. If you can’t find Lyme (Dearborn misses 85% of the cases) then your “vaccine” will apparently “work.” The CDC admits there are 300,000 new tick bite cases per year, but at 15% accuracy the real number is 2 million. Half will go on to permanent disability, according to the cabal’s own earlier publications.

Ultimately, the FDA issued an ultimatum to SmithKline to remove LYMErix from the market, or the FDA would “pull it,” themselves. To this day, the media repeat the lie that the “vaccine” was voluntarily discontinued due to poor sales. In reality, the FDA handed SmithKline a “Get Out of Jail Free” card.

Slander, libel, perjury, harassment, and denial of access to any kind of care are the obvious tools and outcomes of this anti-competetive activity of fraudulent patent enforcement. In this case, it is the ALDF-associated CDC officers who act under color of law to deny access to medical care by enforcing their fake “guidelines” which are based on their fake Dearborn definition of Lyme disease that excludes all cases of neurologic Lyme and includes only Lyme arthritis.

We reference Title 18, U.S.C., Section 242: “Whoever, under color of law…willfully subjects any person…to the deprivation of any rights, privileges, or immunities secured or protected by the Constitution or laws of the United States…shall be fined under this title or imprisoned for any term of years or for life…or may be sentenced to death.”

We expect that these criminals will be prosecuted to the fullest extent of this law, having used their position as government officials to not only profit from a product that they knew to be harmful, but to continually torture their victims through the ongoing concealment of their crimes.

FIXING THE FALSIFIED CASE DEFINITION/DIAGNOSTIC TESTING IS NOT ENOUGH.

Unless the guilty are prosecuted and the scientific evidence is brought into a courtroom, the victims will continue to face deprivation of rights. They will not have access to medical care for the immunosuppression disease of tick bite post sepsis if the testing, only, is addressed.

In addition to these human rights crimes against the victims, the scientific world has to know you can’t use a fungal, triacyl lipoprotein such as OspA/Pam3Cys as a human vaccine or adjuvant, since it is more toxic than a typical bacterial lipopolysaccharide (LPS) – a known and formal endotoxin. Much damage has been done to medical science already. We could have known in the mid-1990s that Multiple Sclerosis and Lupus are initiated by a sepsis event like Lyme or LYMErix disease, whereupon the latent herpes viruses are reactivated. The cabal themselves reported that chronic, neurologic Lyme appeared to reactivate Epstein-Barr and cause systemic, sepsis-like damage (Steere, 1988, IDSA, 1989)

For all the details about what they did, when, where, why and how they did it—fully cited with published research (mostly by the perpetrators themselves), please read: https://www.truthcures.org/charge-sheets

Friday, October 6, 2017

Nothing Boring About Boron




Nothing Boring About Boron

Lara Pizzorno, MDiv, MA, LMT
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712861/


BORON AS AN ANTIFUNGAL

Abstract

Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade®), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin’s lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

BORON made into a paste with distilled water is deadly on MRSA BOILS.